Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial

Ingo K. Mellinghoff[#1], **Marta Penas-Prado**[2], **Katherine B. Peters**[3], **Howard A. Burris III**[4], **Elizabeth A. Maher**[5], **Filip Janku**[6], **Gregory M. Cote**[7], **Macarena I. de la Fuente**[8], **Jennifer L. Clarke**[9], **Benjamin M. Ellingson**[10], **Saewon Chun**[11], **Robert J. Young**[12], **Hua Liu**[13,†], **Sung Choe**[13,†], **Min Lu**[13,†], **Kha Le**[13], **Islam Hassan**[13,†], **Lori Steelman**[13,†], **Shuchi S. Pandya**[13,†], **Timothy F. Cloughesy**[#11], **Patrick Y. Wen**[14]

[1]Department of Neurology and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. [2]Neuro-oncology Branch, National Institutes of Health, National Cancer Institute, Bethesda, Maryland. [3]The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina. [4]Sarah Cannon Research Institute, Nashville, Tennessee. [5]Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas. [6]Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. [7]Massachusetts General Hospital Cancer Center, Boston, Massachusetts. [8]Department of Neurology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. [9]Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California. [10]UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California. [11]Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, California. [12]Neuroradiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. [13]Agios Pharmaceuticals, Inc., Cambridge, Massachusetts. [14]Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

[#] These authors contributed equally to this work.

Abstract

Purpose: Lower-grade gliomas (LGGs) are malignant tumors in young adults. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is associated with contrast enhancement on MRI. The majority of LGGs harbor mutations in the genes encoding isocitrate dehydrogenase 1 or 2 (*IDH1/IDH2*). Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.

Experimental Design: We conducted a multicenter, open-label, phase I, dose escalation study of vorasidenib in 93 patients with mutant *IDH1/2* (m*IDH1/2*) solid tumors, including 52 patients with glioma that had recurred or progressed following standard therapy. Vorasidenib was administered orally, once daily, in 28-day cycles until progression or unacceptable toxicity. Enrollment is complete; this trial is registered with ClinicalTrials.gov, NCT02481154.

Results: Vorasidenib showed a favorable safety profile in the glioma cohort. Dose-limiting toxicities of elevated transaminases occurred at doses >100 mg and were reversible. The protocol-defined objective response rate per Response Assessment in Neuro-Oncology criteria for LGG (RANO-LGG) in patients with nonenhancing glioma was 18% (one partial response, three minor responses). The median progression-free survival was 36.8 months [95% confidence interval (CI), 11.2–40.8] for patients with nonenhancing glioma and 3.6 months (95% CI, 1.8–6.5) for patients with enhancing glioma. Exploratory evaluation of tumor volumes in patients with nonenhancing glioma showed sustained tumor shrinkage in multiple patients.

Conclusions: Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with recurrent or progressive nonenhancing m*IDH* LGG.

Introduction

Gliomas represent the most frequent malignant primary brain tumors and are characterized by diffuse infiltration of the brain by malignant cells (1,2). World Health Organization (WHO) grade II and grade III diffuse gliomas are often referred to as lower-grade gliomas (LGGs) (3). LGGs afflict younger patients, initially grow at a slower rate, and typically do not show contrast enhancement on T1-weighted brain MRI at initial disease diagnosis (4,5). Treatment of LGGs includes maximally safe tumor resection, followed by radiation and chemotherapy as appropriate (5,6). Unfortunately, this treatment is not curative and most patients suffer disease recurrence and progress to a higher tumor grade (7), often associated with aberrant vascularization (8) and the appearance of tumor contrast enhancement on T1-weighted brain MRI (5). Even patients with long-term disease control suffer from disease-related or treatment-related symptoms, including neurocognitive changes (5,9,10). New treatment approaches targeting disease-defining genetic events at the earliest stage of the disease may delay the need for DNA-damaging therapies and perhaps delay the transformation of LGGs into more aggressive tumors.

Mutations in the metabolic enzymes isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in various human malignancies, including acute myeloid leukemia (AML), cholangiocarcinoma, and glioma. They occur in up to ~80% of patients with LGGs (range, 2.4%–82.1%) (3). Cancer-associated IDH1/2 mutations occur early in tumorigenesis, cluster in the active site of the enzymes, and cause the mutant enzymes to produce D-2-

hydroxyglutarate (2-HG) (11,12). Accumulation of 2-HG leads to competitive inhibition of potentially >60 α-ketoglutarate–dependent enzymes, causing epigenetic dysregulation and impaired differentiation (13,14). Given the central role of 2-HG in the molecular pathogenesis of mutant *IDH1/2* (m*IDH1/2*) cancer (13,14), pharmacological blockade of mIDH enzymes is being pursued as a potential therapy. Inhibition of mIDH1/2 restored differentiation in experimental models of m*IDH1/2* glioma, leukemia, and cholangiocarcinoma (15–17). Patients with relapsed or refractory AML harboring m*IDH1* or m*IDH2* showed clinical responses to isoform-selective inhibitors of mIDH1 (ivosidenib) and mIDH2 (enasidenib), respectively (18,19). Ivosidenib also showed antitumor activity in patients with m*IDH1* gliomas (20).

Vorasidenib (AG-881), a first-in-class, dual inhibitor of mIDH1/2, was specifically developed for improved penetration across the blood-brain barrier, and showed brain penetrance and reduced tumor growth in an orthotopic model of m*IDH* glioma (21,22). Dual inhibition of mIDH1 and mIDH2 may be superior to isoform-selective inhibition of mIDH1 or mIDH2 because isoform switching from mIDH1 to mIDH2, or vice versa, has been reported as a potential mechanism of acquired resistance in AML (23). Here, we report the results of a phase I study of vorasidenib in patients with advanced m*IDH1/2* solid tumors, with a focus on glioma.

Materials and Methods

Study design and oversight

This phase I, single-arm, multicenter, open-label, dose escalation study of vorasidenib enrolled patients with m*IDH1/2* advanced solid tumors, including glioma (ClinicalTrials.gov, NCT02481154).

Vorasidenib was administered orally, once daily (QD), in continuous 28-day cycles. Dose escalation was conducted separately for glioma and non-glioma solid tumors. Cohorts of three to six evaluable patients were to be enrolled, including at least six patients receiving the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). Additional cohorts of one to six patients could be enrolled at any dose level below the estimated MTD or RP2D for the replacement of patients not evaluable for the dose escalation, the evaluation of alternative dosing regimens, or for further analyses used for RP2D selection. At least 18 patients in the glioma cohort and 21 in the non-glioma cohort were expected to be treated.

The study was conducted according to International Conference on Harmonisation of Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The protocol was approved by the Institutional Review Board/International Ethics Committee at each study location. Written informed consent was provided by all patients before screening and enrollment. The complete study protocol is available in the Supplementary Material.

Patients

All enrolled patients had a confirmed diagnosis of solid tumor, including glioma, with documented m*IDH1* or m*IDH2* that had recurred after—or had not responded to—initial standard therapy. *IDH1/2* mutation status was assessed locally. Eligible patients were aged

18 years, had an Eastern Cooperative Oncology Group performance status score of 0–2, and evaluable disease assessed using Response Assessment in Neuro-Oncology (RANO) or RANO-LGG criteria for patients with glioma, or Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for patients with non-glioma solid tumors (24–26).

Other eligibility criteria included an expected survival of 3 months and adequate bone marrow, hepatic, and renal function. Patients were excluded if they had received systemic anticancer therapy or radiotherapy <21 days before their first day of study drug administration, prior treatment with bevacizumab at any time, or an investigational agent <14 days before their first day of study drug administration. Patients with glioma had a baseline brain MRI scan within 14 days before day 1 while not receiving glucocorticoids, or receiving the same daily dose of glucocorticoids, during the 5 days before the baseline MRI scan.

Study assessments

The primary objectives were to evaluate the safety and tolerability of vorasidenib treatment and to determine the MTD and/or RP2D. Safety evaluation included the incidence of dose-limiting toxicities (DLTs) during the first treatment cycle and adverse events (AEs), serious AEs, and AEs leading to discontinuation.

Secondary objectives included clinical activity as measured by best overall response and progression-free survival (PFS). For enhancing glioma and non-glioma solid tumors, objective response was defined as complete response (CR) or partial response (PR), as determined by the investigator on the basis of RANO criteria (24) or RECIST version 1.1 (26), respectively. For patients with nonenhancing glioma, objective response was defined as CR, PR, and minor response (mR) as determined by the investigator on the basis of RANO-LGG (25). Given the challenges associated with accurate representation of tumor response on MRI in LGG, the RANO working group considers a 25–50% reduction in tumor size compared to baseline clinically meaningful, and several classifications now include mR as a measure of treatment effect (25, 27). Therefore, mR was included in the objective response rate for nonenhancing glioma.. PFS was defined as the time from first dose to the date of progression or death, whichever occurred first. Blood samples were drawn pre- and postdose to determine circulating levels of vorasidenib.

Patients attended study center visits as outlined in the schedule of assessments (Supplementary Methods).

Exploratory assessments

Tumor volume measurements were evaluated in the nonenhancing glioma cohort as previously described (20). Exploratory assessments also included confirmation of baseline m*IDH1/2* status and identification of co-occurring mutations by next-generation sequencing using the ACE Extended Cancer Panel (Personalis, Menlo Park, CA) whenever archival formalin-fixed paraffin-embedded samples were available.

Statistical analysis

The safety analysis set included all patients who received at least one dose of study treatment. The dose-determining set comprised all patients considered evaluable for DLT assessment and MTD estimation [i.e., patients either had a DLT during cycle 1 or completed ≥75% of their planned cycle 1 doses (21 out of 28 days) and were considered by the clinical study team to have had sufficient safety data available to conclude that a DLT did not occur during cycle 1]. AEs occurring after cycle 1 may have been designated as DLTs by the study team.

An adaptive Bayesian logistic regression model (BLRM) with two parameters guided by the escalation with overdose control principle (28) was used to make dose recommendations and estimate the MTD/RP2D. Dose escalation decisions were based on all relevant data available for patients in the dose-determining set from all dose levels evaluated in the study, including observed toxicities and estimates of probability of DLTs using BLRM, safety information, and pharmacokinetic/pharmacodynamic data.

Disposition, demographic and baseline characteristics, safety, and pharmacokinetic parameters were summarized using frequency distributions or descriptive statistics.

Objective response rates were calculated along with two-sided 95% confidence intervals (CIs). All time-to-event outcomes were estimated using Kaplan-Meier methods. Point estimates and 95% CIs were calculated. Estimates of the median and other quantiles were generated.

Data from the non-glioma solid tumor and glioma cohorts were analyzed separately in all analyses.

Role of the funding source

The study was designed by the sponsor in collaboration with the lead investigators. Clinical data were generated by investigators and research staff at each participating site. Safety data were reviewed at regular intervals by investigators and by the sponsor, which also had a role in data collection, analysis, and interpretation. I.K. Mellinghoff and T.F. Cloughesy wrote the first draft of the manuscript and had final responsibility for the decision to submit for publication. Further medical writing support was provided by the sponsor.

Results

Patients

Patients were enrolled from June 18, 2015, through June 23, 2017, across 10 sites in the United States. At the analysis cutoff date (April 29, 2020), the study was ongoing. Overall, 93 patients with m*IDH1/2* advanced solid tumors were treated, including 52 patients with glioma (Table 1).

The glioma cohort included 22 patients with nonenhancing glioma (absence of enhancement on MRI by investigator assessment) and 30 with enhancing glioma. The median age of the patients with glioma was 42.5 (range, 16–73) years. Nearly all patients with glioma had

WHO grade II [25 (48.1%)] or WHO grade III [22 (42.3%)] tumors as of the most recent assessment before screening. Most tumors harbored a mutation in *IDH1* (92.3%). Thirty-nine (75.0%) patients had received prior systemic therapy for the treatment of glioma and 30 (57.7%) had received prior radiation therapy. Eight (36.4%) patients with nonenhancing glioma remained on treatment, with 10 (45.5%) discontinuing treatment due to disease progression, two (9.1%) due to AEs, and two (9.1%) withdrawing from the study. One (3.3%) patient with enhancing glioma remained on treatment, with 24 (80.0%) discontinuing due to progressive disease and five (16.7%) withdrawing from the study. Patient disposition is reported in Supplementary Fig. S1.

The non-glioma cohort (*n* = 41) comprised patients with a variety of other solid tumors. Most patients had an m*IDH1* tumor [27 (65.9%); Table 1] and most had received prior systemic therapies. Enrollment to this cohort was stopped by the sponsor in October 2016, in favor of continued development in glioma.

Safety

The initial starting dose was 25 mg QD. Dose escalation up to 300 mg QD in glioma and 400 mg QD in non-glioma was initially completed (Supplementary Table S1). Based on DLTs of elevated serum transaminases in patients with glioma, an additional 10 mg QD level was opened and an additional six patients were enrolled in the 50 mg QD dose level. Five AEs of grade 2 elevated transaminases that occurred at 100 mg in patients with glioma were designated as DLTs by the sponsor. Transaminase AEs were dose dependent (Supplementary Table S2), not associated with a bilirubin elevation, and resolved to grade 1 with dose modification or discontinuation. Two patients discontinued due to this AE. The MTD was not reached in the glioma cohort based on BLRM; dose selection could be guided by the BLRM but was not dependent upon the BLRM. Based on dose-dependent DLTs, the sponsor and investigators recommended no further escalation beyond 300 mg, and that doses <100 mg be further explored in glioma. No DLTs were observed and the MTD had not been reached at doses of up to 400 mg QD in patients with non-glioma tumors before termination of enrollment in this cohort based on the sponsor's decision to focus the development of vorasidenib exclusively in glioma.

The most common (>10%) AEs are reported in Table 2. Ten (19.2%) patients with glioma and 19 (46.3%) with non-glioma tumors experienced a grade 3 AE. The most common grade 3 AEs among patients with glioma were seizure [four (7.7%)] and increased plasma concentrations of alanine aminotransferase [three (5.8%)] and aspartate aminotransferase [two (3.8%)]. In the glioma cohort, two (3.8%) patients discontinued due to AEs and seven (13.5%) required a dose reduction due to AEs. Treatment-related AEs were reported in 38 (73.1%) patients with glioma and 26 (63.4%) with non-glioma tumors. There were no treatment-related deaths.

Efficacy

In patients with nonenhancing glioma (*n* = 22), the objective response rate (CR+PR+mR) by investigator was 18%, including one PR (patient #22) and three mR (patients #19, #20, and #21). All four responses were sustained, ranging from 7.4 to 27.7 months in duration.

Sixteen (72.7%) patients had stable disease as their best response, many with reductions in the sum of products of the diameters <25%, which did not qualify for mR (Fig. 1A; Table 3).

No patients with enhancing glioma had a confirmed radiographic response and 17 of 30 (56.7%) had stable disease as their best response. One patient with contrast-enhancing anaplastic oligodendroglioma (patient #25) had >50% reduction in the sum of products of the diameters that was not confirmed, and the patient was therefore categorized as stable disease (Fig. 1A; Table 3).

The median (range) treatment duration was 26.8 (1.0–50.9) months for nonenhancing glioma and 3.3 (0.2–53.6) months for enhancing glioma. Fifteen (68.2%) patients with nonenhancing disease and four (13.3%) with enhancing disease remained on treatment for >1 year (Fig. 1B).

With 75% of events reported, the median PFS in the overall glioma population was 7.5 months (95% CI, 3.7–12.9; Fig. 1C). In patients with nonenhancing glioma, the median PFS was 36.8 months (95% CI, 11.2–40.8), with 59% of events reported and six of nine censored patients remaining on treatment (range of PFS for these six patients, 33.2–49.6 months). In patients with enhancing glioma, the median PFS was 3.6 months (95% CI, 1.8–6.5). Efficacy results for the non-glioma cohort are provided in the Supplementary Results.

Pharmacokinetics

Pharmacokinetic analyses were performed for the glioma and non-glioma cohorts separately as of March 11, 2019 (Supplementary Table S3). A dose-proportional increase in plasma exposure of vorasidenib was observed in patients with glioma at doses of 10–300 mg, and less than dose proportional in patients with non-glioma tumors at doses of 25–400 mg. Vorasidenib had a long half-life (46.9–87.3 hours in glioma; 45.5–176 hours in non-glioma).

Exploratory findings

Targeted sequencing was performed on archival tumor samples from 18 patients with enhancing glioma and 11 with nonenhancing glioma (Supplementary Fig. S2). There was no association identified between any single gene mutation and tumor response in this small sample set.

Evaluation of posttreatment tumor volumes by MRI was centrally performed for 21 of 22 patients with nonenhancing glioma. Additional *post hoc* analysis of pre- and posttreatment volume measurements was performed for three patients with available historical MRIs (patients #15, #19, and #22). Visual inspection of the images, as well as sequential tumor volume measurements, showed tumor shrinkage following the initiation of vorasidenib (Fig. 2).

Discussion

Standard therapy for patients with LGGs includes maximally safe surgical tumor resection, with additional radiation and chemotherapy for high-risk tumors (5,6). This treatment is not curative and most patients with LGG suffer considerable morbidity and premature

death (5,9). There remains an urgent need to develop novel treatment paradigms. Our study describes the first-in-human evaluation of vorasidenib, a dual *mIDH1/2* inhibitor specifically developed for increased blood-brain barrier penetrance, in glioma. Our study was associated with a favorable safety profile at doses <100 mg QD in this previously treated glioma population, with many patients remaining on treatment after several years of continuous treatment. Based on safety and pharmacokinetic data from this study, doses of 50 mg QD and 10 mg QD were tested in a subsequent perioperative phase I study in patients with nonenhancing glioma (ClinicalTrials.gov, NCT03343197). Preliminary data from that study confirmed sufficient CNS concentrations of vorasidenib 50 mg QD and >90% reduction in intratumoral 2-HG concentrations compared with untreated controls, indicating near complete inhibition of the enzyme (29). Based on the findings from these phase I studies, a vorasidenib dose of 50 mg QD was selected for further study in m*IDH* glioma.

Vorasidenib showed preliminary activity in patients with nonenhancing glioma, with an objective response rate (CR+PR+mR) of 18% (one PR, three mR) and a median PFS of 36.8 months. Although comparisons with historical data are difficult to make due to differences in patient populations and the heterogeneity of prior treatments in this recurrent patient population, the median PFS for patients with nonenhancing disease in our study compares favorably with outcomes reported for cytotoxic therapies (30,31). Despite lacking historical MRI scans for all patients, sustained tumor shrinkage was observed in multiple patients with nonenhancing glioma with vorasidenib treatment. In contrast, there was no indication of antitumor activity of vorasidenib in patients with enhancing tumors (no objective responses; PFS 3.6 months), reminiscent of our earlier findings with the mIDH1 inhibitor ivosidenib (20). The lack of single-agent antitumor efficacy of vorasidenib in patients with enhancing gliomas may be due to the presence of additional genetic alterations in these tumors that can bypass the need for the mIDH enzyme for tumor maintenance. Although this explanation seems plausible, given the general association between contrast enhancement and genetic tumor evolution in LGG (32), we are unable to address this question in our current study because our protocol did not mandate a tumor biopsy and genomic sequencing immediately preceding study enrollment.

A watch-and-wait approach following surgery remains a treatment option for patients with low-risk LGG. Given the acute and long-term toxicities associated with—and additional genetic alterations at disease recurrence resulting from—alkylating chemotherapy and radiation treatment for glioma (9,10,33), there is an opportunity to introduce a targeted therapy against a potential driver *IDH* mutation during the active observation period, in the hopes of delaying more toxic therapies and preserving quality of life for a younger patient population. The favorable safety profile and single-agent activity of vorasidenib in recurrent, progressive nonenhancing glioma in our current study support the further exploration of vorasidenib in the earliest stages of m*IDH* LGG, compared with a watch-and-wait approach. To that end, vorasidenib (50 mg QD) is being tested versus placebo in the ongoing, randomized, phase III INDIGO study (ClinicalTrials.gov, NCT04164901). The INDIGO study is enrolling patients with recurrent grade II nonenhancing m*IDH* glioma treated with surgery only, and will seek to offer additional insight into the antitumor activity of vorasidenib at an early stage of disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Authors' Disclosures

I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc., Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen, Eli Lilly, and General Electric. This article was prepared while M. Penas-Prado was employed at The University of Texas MD Anderson Cancer Center. The opinions expressed in this article are the author's own and do not reflect the views of the National Institutes of Health, the Department of Health and Human Services, or the United States Government. K.B. Peters reports serving as an advisory board member for Agios Pharmaceuticals, Inc., and Bayer, and research grants from AbbVie, Agios Pharmaceuticals, Inc., BioMimetix, Bristol Myers Squibb, Novocure, and Tesoro. F. Janku reports research support through institution from Agios Pharmaceuticals, Inc., Asana, Astellas, Bicara, BioMed Valley Discoveries, Bristol Myers Squibb, Deciphera, Fujifilm, Genentech, IDEAYA, Novartis, Plexxikon, PIQUR, Proximagen, SOTIO, Symphogen, and Synthorx, serving on scientific advisory boards for Deciphera, Guardant Health, IDEAYA, IFM, Illumina, PureTech Health, SOTIO, and Synlogic, consulting fees from Cardiff Oncology and Immunomet, and ownership interests in Cardiff Oncology. G.M. Cote reports serving as an advisory board member or consultant for Agios Pharmaceuticals, Inc., Epizyme, and PharmaMar, and clinical trial research support from Eisai, Merck KGaA/EMD Sorono Research and Development Institute, and PharmaMar. M.I. de la Fuente reports serving as an advisory board member or consultant for Agios Pharmaceuticals, Inc., Forma, Foundation Medicine, and Puma Biotechnology. J.L. Clarke reports serving as a consultant for Agios Pharmaceuticals, Inc., and research grants from Agios Pharmaceuticals, Inc., and Merck & Co. B.M. Ellingson reports serving as a consultant for Agios Pharmaceuticals, Inc., BBI, BeiGene, Imaging Endpoints, Janssen, Kazia, Medicenna, MedQIA, Neosoma, Northwest Biotherapeutics, Oncoceutics, Siemens, Tocagen, and VBL, and research grants from F. Hoffmann-La Roche, Janssen, and Siemens. R.J. Young reports serving as a consultant for Agios Pharmaceuticals, Inc., ICON, NordicNeuroLab, and Puma Biotechnology, research grants from Agios Pharmaceuticals, Inc., and is a stockholder of Agios Pharmaceuticals, Inc., Alexion, Amgen, Biogen, Bristol Myers Squibb, Celgene, Gilead, Merck, Regeneron, and Vertex. H. Liu, S. Choe, M. Lu, I. Hassan, and S.S. Pandya were employees and stockholders of Agios Pharmaceuticals, Inc., at the time of the study, and are now employees of Servier Pharmaceuticals, LLC. K. Le was an employee and stockholder of Agios Pharmaceuticals, Inc., at the time of the study. L. Steelman was an employee and stockholder of Agios Pharmaceuticals, Inc., at the time of the study, is now an employee of Servier Pharmaceuticals, LLC, and is a stockholder of Infinity. T.F. Cloughesy reports serving as a consultant for AbbVie, Agios Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cortice Biosciences, Deciphera, GW, Human Longevity, Insys Therapeutics, Karyopharm, KIYATEC, MedQIA, Notable Labs, Novocure, Pfizer, Sierra Oncology, Sumitomo Dainippon Pharma, Tocagen, VBI Vaccines, and VBL, research grants from AbbVie, Agios Pharmaceuticals, Inc., Amgen, AstraZeneca, Bristol Myers Squibb, Deciphera, DNAtrix, Eli Lilly, F. Hoffmann-La Roche, Genocea Biosciences, Karyopharm, Kazia, Merck & Co, OrbusNeich, Sumitomo Dainippon Pharma, and Tocagen, and is a stockholder of Notable Labs. P.Y. Wen reports serving on advisory boards for Agios Pharmaceuticals, Inc., AstraZeneca, Bayer, Boston Pharmaceuticals, CNS, ElevateBio, Immunomic Therapeutics, Imvax, Karyopharm, KIYATEC, Merck, Novartis, QED, Tocagen, Vascular Biogenics, VBI Vaccines, and Voyager, research support from Agios Pharmaceuticals, Inc., AstraZeneca/ MedImmune, BeiGene, Celgene, Eli Lilly, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Oncoceutics, Vascular Biogenics, and VBI Vaccines.

References

1. GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol2019;18:376–93. [PubMed: 30797715]

2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol2016;131:803–20. [PubMed: 27157931]

3. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med2015;372:2481–98. [PubMed: 26061751]

4. Pallud J, Capelle L, Taillandier L, Fontaine D, Mandonnet E, Guillevin R, et al.Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol2009;11:176–82. [PubMed: 18697954]

5. van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol2017;35:2394–401. [PubMed: 28640702]

6. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al.EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol2021;18:170–86. [PubMed: 33293629]

7. Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, et al.Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus2015;38:E6.

8. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol2012;181:1126–41. [PubMed: 22858156]

9. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al.Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet2002;360:1361–8. [PubMed: 12423981]

10. McAleer MF, Brown PD. Neurocognitive function following therapy for low-grade gliomas. Semin Radiat Oncol2015;25:210–8. [PubMed: 26050592]

11. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature2010;465:966. [PubMed: 20559394]

12. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al.The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell2010;17:225–34. [PubMed: 20171147]

13. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al.IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature2012;483:474–8. [PubMed: 22343901]

14. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al.Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell2011;19:17–30. [PubMed: 21251613]

15. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al.An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science2013;340:626–30. [PubMed: 23558169]

16. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al.Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science2013;340:622–6. [PubMed: 23558173]

17. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al.Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature2014;513:110–4. [PubMed: 25043045]

18. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al.Durable remissions with ivosidenib in *IDH1*-mutated relapsed or refractory AML. N Engl J Med2018;378:2386–98. [PubMed: 29860938]

19. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al.Enasidenib in mutant *IDH2* relapsed or refractory acute myeloid leukemia. Blood2017;130:722–31. [PubMed: 28588020]

20. Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al.Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol2020;38:3398–406. [PubMed: 32530764]

21. Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, et al.Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett2020;11:101–7. [PubMed: 32071674]

22. Nicolay B, Narayanaswamy R, Amatangelo MD, Aguado E, Nagaraja R, Murtie J, et al.EXTH-34. Combined use of the pan-IDH mutant inhibitor AG-881 with radiation therapy shows added benefit in an orthotopic idh1 mutant glioma model *in vivo*. Neuro Oncol2017;19(suppl 6):vi79.

23. Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, et al.Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov2018;8:1540–7. [PubMed: 30355724]

24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al.Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol2010;28:1963–72. [PubMed: 20231676]

25. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al.Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol2011;12:583–93. [PubMed: 21474379]

26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009;45:228–47. [PubMed: 19097774]

27. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al.Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol2015;16:e534–42. [PubMed: 26545842]

28. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med2008;27:2420–39. [PubMed: 18344187]

29. Mellinghoff I, Cloughesy T, Wen P, Taylor J, Maher E, Arrillaga-Romany I, et al.ACTR-66. A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent IDH1 mutant, low-grade glioma: updated results. Neuro Oncol2019;21(suppl 6):vi28–9.

30. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al.Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol2016;17:1521–32. [PubMed: 27686946]

31. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al.IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology2010;75:1560–6. [PubMed: 20975057]

32. Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, et al.Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin Cancer Res2019;25:5537–47. [PubMed: 31263031]

33. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al.Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science2014;343:189–93. [PubMed: 24336570]

Translational Relevance

Standard treatments of surgery, chemotherapy, and radiotherapy for diffuse lower-grade gliomas (WHO grade II/III) are noncurative. Tumors recur and progress to a higher grade in most patients. Patients with long-term disease control often experience disease- or treatment-related symptoms. Vorasidenib, a first-in-class, brain-penetrant dual inhibitor of mutant IDH1/2 (mIDH1/2), reduced tumor growth and levels of the oncometabolite D-2-hydroxyglutarate in an orthotopic m*IDH* glioma mouse model. In this phase I, first-in-human study, vorasidenib showed a favorable safety profile at doses <100 mg once daily and preliminary clinical activity in recurrent or progressive m*IDH1/2* glioma. Although these patients had recurrent disease after—or had not responded to—initial standard therapy, these results suggest a potential benefit of introducing mIDH-targeted therapy during the watch-and-wait period, which could potentially delay the use of more toxic treatments. Moreover, they provide the rationale for the continued evaluation of vorasidenib in an ongoing placebo-controlled, randomized, phase III study (ClinicalTrials.gov, NCT04164901).

Figure 1.
Clinical activity and efficacy of vorasidenib in patients with glioma. **A,** Best response in evaluable patients with measurable disease (25 enhancing and 22 nonenhancing) expressed as the percentage change in SPD from the target lesions at start of treatment. Among the 52 patients, four patients with enhancing disease had evaluable but nonmeasurable disease, and one withdrew from the study before tumor response evaluations. **B (left panel),** Treatment duration and best response for patients with nonenhancing glioma; eight patients remained on treatment. **B (right panel),** Treatment duration and best response for

patients with enhancing glioma; one patient remained on treatment. In **A** and **B**, shaded patient case ID numbers (#) written in bold brown font indicate patients with nonenhancing glioma for whom brain MRI images and volumetric growth curves are shown in Fig. 2. **C,** Investigator-assessed PFS according to glioma type and for glioma overall for all patients (N = 52), with tick marks indicating censored observations. [a]Lesion growth >100%. [b]An mR is defined as a ≥25% but <50% decrease in tumor measurements relative to baseline. [c]A >50% decrease in tumor measurements relative to baseline corresponds to a PR. A >50% reduction from baseline was not confirmed with subsequent scan in one patient with nonenhancing disease and was therefore categorized as mR. One patient with enhancing disease had a >50% reduction that was not confirmed and was categorized as SD. Abbreviations: PD=progressive disease. SD=stable disease. SPD=sum of products of the diameters.

Figure 2.
Brain MRI and volume growth curves in three patients with nonenhancing glioma treated with vorasidenib. Visual inspection of the images, as well as tumor size and volume measurements, showed tumor shrinkage after vorasidenib treatment. **A,** Patient #15 is a 47-year-old male with an anaplastic astrocytoma that was initially treated with surgery, radiotherapy, and procarbazine/CCNU/vincristine. Best response as of data cutoff: stable disease. **B,** Patient #19 is a 40-year-old female with an oligoastrocytoma that was initially treated with surgery and temozolomide. Best response as of data cutoff: mR. **C,** Patient #22 is a 49-year-old female with an oligodendroglioma that was initially treated with surgery and no other treatment. Best response as of data cutoff: PR. Scan collection time points relative to first dose and corresponding on-treatment cycle numbers are shown.

Table 1.

Baseline characteristics.

Characteristic	Nonenhancing glioma (*n* = 22)	Enhancing glioma (*n* = 30)	Glioma overall (*n* = 52)	Non-glioma[a] (*n* = 41)
Age in years	47.0 (16–73)[b]	40.1 (18–59)	42.5 (16–73)[b]	57.0 (28–89)
Sex				
Male	8 (36.4)	18 (60.0)	26 (50.0)	14 (34.1)
Female	14 (63.6)	12 (40.0)	26 (50.0)	27 (65.9)
ECOG performance status score at baseline				
0	7 (31.8)	11 (36.7)	18 (34.6)	10 (24.4)
1	13 (59.1)	18 (60.0)	31 (59.6)	28 (68.3)
2	0	1 (3.3)	1 (1.9)	3 (7.3)
Unknown	2 (9.1)	-	2 (3.8)	-
IDH mutation[c]				
IDH1	20 (90.9)	28 (93.3)	48 (92.3)	27 (65.9)
IDH2	1 (4.5)	2 (6.7)	3 (5.8)	14 (34.1)
WHO tumor grade at screening				
Grade II	17 (77.3)	8 (26.7)	25 (48.1)	-
Grade III	5 (22.7)	17 (56.7)	22 (42.3)	-
Grade IV	0	4 (13.3)	4 (7.7)	-
Unknown[c]	0	1 (3.3)	1 (1.9)	-
1p19q				
Intact	9 (40.9)	11 (36.7)	20 (38.5)	-
Deleted	8 (36.4)	8 (26.7)	16 (30.8)	-
Unknown	5 (22.7)	11 (36.7)	16 (30.8)	-
Prior surgery only	7 (31.8)	4 (13.3)	11 (21.2)	2 (4.9)
Prior radiation therapy				
Yes	8 (36.4)	22 (73.3)	30 (57.7)	9 (22.0)
Prior systemic therapy				
Yes	14 (63.6)	25 (83.3)	39 (75.0)	38 (92.7)
Number of prior systemic therapies	2 (1–4)	2 (1–6)	2 (1–6)	2 (1–7)

Note: Data are median (range) or *n* (%) unless otherwise stated.

[a] See Supplementary Fig. S1 for the included non-glioma solid tumors.

[b] A 16-year-old patient was enrolled in the study through an eligibility waiver.

[c] One patient with nonenhancing glioma did not have any prior biopsy; grade of tumor is therefore unknown. *IDH* mutation was presumed by the investigator as evidenced by consistent 2-HG elevation by magnetic resonance spectroscopy.

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Table 2.

Summary of overall and most common treatment-emergent AEs.

Event	Glioma (*n* = 52)		Non-glioma (*n* = 41)	
	Any grade	Grade 3	Any grade	Grade 3
Any AE	52 (100.0)	10 (19.2)	41 (100.0)	19 (46.3)
Any serious AE	9 (17.3)	5 (9.6)	8 (19.5)	0
Any related AE	38 (73.1)	4 (7.7)	26 (63.4)	0
Any serious related AE	4 (7.7)	4 (7.7)	0	0
Most common AEs (>10%)				
Headache	24 (46.2)	0	6 (14.6)	0
Alanine aminotransferase increased	23 (44.2)	3 (5.8)	9 (22.0)	1 (2.4)
Aspartate aminotransferase increased	21 (40.4)	2 (3.8)	12 (29.3)	1 (2.4)
Fatigue	17 (32.7)	1 (1.9)	19 (46.3)	1 (2.4)
Nausea	17 (32.7)	1 (1.9)	19 (46.3)	1 (2.4)
Seizure	15 (28.8)	4 (7.7)	1 (2.4)	1 (2.4)
Hyperglycemia	10 (19.2)	0	2 (4.9)	1 (2.4)
Vomiting	10 (19.2)	1 (1.9)	15 (36.6)	1 (2.4)
Constipation	9 (17.3)	0	15 (36.6)	0
Dizziness	9 (17.3)	0	3 (7.3)	0
Neutrophil count decreased	9 (17.3)	1 (1.9)	1 (2.4)	0
Cough	8 (15.4)	0	5 (12.2)	0
Diarrhea	8 (15.4)	0	8 (19.5)	0
White blood cell count decreased	7 (13.5)	0	0	0
Aphasia	6 (11.5)	0	0	0
Hypoglycemia	6 (11.5)	0	1 (2.4)	0
Upper respiratory tract infection	6 (11.5)	0	1 (2.4)	0

Note: Data are *n* (%). Any-grade treatment-emergent AEs occurring in >10% of the glioma population, along with their frequency as grade 3 events, are shown. The corresponding frequencies for the non-glioma cohort are also shown. AEs were graded using the Common Terminology Criteria for Adverse Events version 4.03.

Table 3.

Best overall response by RANO or RANO-LGG in patients with glioma, according to the investigator.

Response	Nonenhancing glioma (*n* = 22)	Enhancing glioma (*n* = 30)
Best overall response		
Complete response	0	0
Partial response[a]	1 (4.5)	0
Minor response[b]	3 (13.6)	-
Stable disease	16 (72.7)	17 (56.7)
Progressive disease	2 (9.1)	12 (40.0)
Missing	0	1 (3.3)
Objective response rate[c]	4 (18.2) [95% CI, 5.2–40.3]	0 [95% CI, 0–11.6]

Note: Data are *n* (%). Enhancing glioma was assessed by RANO and nonenhancing glioma by RANO-LGG.

[a] Dose received at the time the response occurred: 50 mg QD.

[b] Dose received at the time the response occurred: 200 mg QD.

[c] Complete response, partial response, or minor response.